Niacin Patent Expiration
Niacin is Used for treating hyperlipidemia by dosing once daily in the evening or at night to reduce elevated total cholesterol, LDL cholesterol, and triglyceride levels, and increase HDL cholesterol levels. It was first introduced by Medpointe Pharmaceuticals Medpointe Healthcare Inc
Niacin Patents
Given below is the list of patents protecting Niacin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Niaspan | US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar 15, 2018
(Expired) | Abbvie |
| Niaspan | US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May 27, 2017
(Expired) | Abbvie |
| Niaspan Titration Starter Pack | US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May 27, 2017
(Expired) | Abbvie |
| Niaspan | US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Feb 15, 2014
(Expired) | Abbvie |
| Niaspan | US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan | US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan | US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan | US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan | US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan | US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan | US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan Titration Starter Pack | US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan Titration Starter Pack | US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan Titration Starter Pack | US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep 20, 2013
(Expired) | Abbvie |
| Niaspan Titration Starter Pack | US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep 20, 2013
(Expired) | Abbvie |
Niacin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Niacin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
